Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 1/20 | 0.52 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.50 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 4/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28439801 | 0.84 | AKR1C3 (0.54) | AKR1C3ALOX5KMT2ATDP1HPGD | |
| SCHEMBL28283295 | 0.78 | AKR1C3 (0.64) | AKR1C3ALOX5KMT2ATDP1HPGD | |
| SCHEMBL11527185 | 0.78 | SMN1; SMN2 (0.71) | KMT2ATDP1SMN1; SMN2RAB9AMAPT | |
| SCHEMBL31321650 | 0.77 | AKR1C3 (0.66) | AKR1C3ALOX5KMT2AHPGDPOLB | |
| SCHEMBL28040073 | 0.76 | KMT2A (0.57) | AKR1C3ALOX5KMT2AHPGDMAPT | |
| SCHEMBL22528727 | 0.76 | TDP1 (0.53) | AKR1C3KMT2ATDP1SMN1; SMN2NPC1 | |
| SCHEMBL28062064 | 0.75 | TDP1 (0.56) | AKR1C3KMT2ATDP1SMN1; SMN2MAPT | |
| SCHEMBL8122320 | 0.75 | AKR1C3 (0.60) | AKR1C3ALOX5KMT2AHPGDNPC1 | |
| SCHEMBL22499185 | 0.73 | TDP1 (0.58) | AKR1C3ALOX5KMT2ATDP1SMN1; SMN2 | |
| SCHEMBL31321719 | 0.73 | AKR1C3 (0.65) | AKR1C3ALOX5KMT2ATDP1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080146844-A1 | PROCESS FOR PREPARING TOLTERODINE | DR. REDDY'S LABORATORIES LIMITED (IN) | 2008-06-19 | — | — | US | disclosed |
| EP-1419135-A4 | PROCESS FOR THE PREPARATION OF TOLTERODINE | RANBAXY LAB LTD (IN) | 2006-01-11 | — | — | EP | disclosed |
| US-6822119-B1 | REACTING 3,4-DIHYDRO-6-METHYL-4-PHENYL-2H-BENZOPYRAN-2-ONE WITH DIMETHYL SULFATE USING PHASE TRANSFER CATALYST; DESTERIFICATION, REDUCTION, AMINATION, SULFONATION, DEPROTECTING, DECYCLIZATION, AND SALT FORMATION | RANBAXY LABORATORIES LIMITED (IN) | 2004-11-23 | — | — | US | disclosed |
| EP-1419135-A1 | PROCESS FOR THE PREPARATION OF TOLTERODINE | RANBAXY LABORATORIES, LTD. (IN) | 2004-05-19 | — | — | EP | disclosed |
| WO-2003014060-A1 | PROCESS FOR THE PREPARATION OF TOLTERODINE | RANBAXY LABORATORIES LIMITED (IN) | 2003-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146844-A1 | PROCESS FOR PREPARING TOLTERODINE | ADRA2B, ADRB3, ADRB1 | AKR1C3 1421/4885PTPN1 3823/4885ALOX5 3454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.